Post-marketing hospital centralized monitoring of clinical safety of Shuganning injection

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ITMCTR

Registry ID

ITMCTR2100004833

Enrollment

Unknown

Registered

2021-05-12

Start date

2021-07-01

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adverse drug reactions

Interventions

Experimental group:Shuganning injection was used

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.During the monitoring period, all inpatients receiving Shuganning injection were observed; 2.The same patient with different times of medication, the interval between two times of medication is less than 3 days ( 3 days), according to the new observation object.

Exclusion criteria

Exclusion criteria: Inpatients who are unable to collect the information needed for this study.

Design outcomes

Primary

Measure	Time frame
ADR/ADE;	—

Countries

China

Contacts

Public ContactLi Xuelin

The First Affiliated Hospital of Henan University of Chinese Medicine

lixuelin450000@163.com+86 371 66245274

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026